The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health officials seek newer information on vaccine results in the global fight against ...

"While the safety of Ixchiq for use in individuals 60 years of age and older is being further assessed, FDA and CDC are recommending a pause in use of the vaccine in this age group.

FDA and CDC recommend pause in use of Ixchiq (chikungunya vaccine, live) in individuals 60 years of age and older while postmarketing safety reports are investigated. May 9, 2025.

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 and older, including death. Hotspots ranked Start the day smarter ☀️ ...

The Ixchiq vaccination, ... (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications.

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a live, weakened form of the virus to trigger immunity.

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in chikungunya-naïve children at day 180.

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health officials seek newer information on vaccine results in the global fight against ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a live, weakened form of the virus to trigger immunity.